University of Southampton
Inhibitors and mechanism of phospho-N-acetylmuramyl-pentapeptide translocase (<i>Escherichia coli</i>)
Abstract
dc:description.abstract<p class="MsoNormal" style="margin-bottom:0cm;line-height:normal;mso-layout-grid-align: none;text-autospace:none">Bacterial drug resistance is an increasingly serious problem facing public health. Consequently there is a continuing need for the development of novel antibacterial agents as therapeutic antibiotics. Bacterial peptidoglycan biosynthesis is a good target for antimicrobial agents since there is no equivalent in mammalian cells. </p> <p class="MsoNormal" style="margin-bottom:0cm;line-height:normal;mso-layout-grid-align: none;text-autospace:none">The first step in the membrane cycle of reactions of bacterial peptidoglycan biosynthesis is transfer of phospho-MurNAc-pentapeptide from UMP to a membrane bound carrier molecule, undecaprenyl phosphate. This step remains an unexploited potential target for antibiotics. This reaction is catalysed by the integral membrane enzyme, phospho-N-acetylmuramyl-pentapeptide translocase (translocase I). The gene coding for this enzyme in <i>Escherichia coli</i>, <i>mraY</i>, has recently been cloned. Two novel classes of antibiotics, the mureidomycins and liposidomycins, have recently been characterised as potent and specific inhibitors of translocase 1.</p> <p class="MsoNormal" style="margin-bottom:0cm;line-height:normal;mso-layout-grid-align: none;text-autospace:none">Translocase I (<i>E. coli</i>) has been overexpressed 30-fold in <i>E. coli</i> and has been solubilised from particulate membranes with retention of catalytic activity. A continuous fluorescence-based assay for translocase I activity has been developed based on the work of Weppner and Neuhaus (W.A. Weppner and F.C. Neuhaus 1977, <i>J. Biol, Chem.</i> 252, 2296-2303). Mureidomycin A is a potent slow-binding inhibitor of translocase I activity with Kj and Kj* values of 36 nM and 2 nM respectively. Liposidomycin B also appears to be a slow-binding inhibitor with a Kj* value of 143 nM. </p> <p class="MsoNormal" style="margin-bottom:0cm;line-height:normal;mso-layout-grid-align: none;text-autospace:none">Evidence has been obtained for a covalent enzyme-linked intermediate involved in the reaction pathway implying a ping pong type mechanism. The intermediate was labile to hydroxylamine suggesting an acyl-phosphate in the active-site. </p> <p class="MsoNormal" style="margin-bottom:0cm;line-height:normal;mso-layout-grid-align: none;text-autospace:none">Sequence alignments have revealed an evolutionary superfamily of phosphor-aminosugar transferase enzymes, of which translocase I is a member. Three aspartate residues conserved through this class of enzymes have been investigated by site-directed mutagenesis as possible active-site nucleophiles. The results are discussed in the context of rational drug design.</p>
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 1995
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Brandish, Philip Edward
Rights
- Language dc:language
- English, eng